Literature DB >> 29246924

The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source.

Barnaby Peacock-Young1, Fraser L Macrae1, Darren J Newton2, Anita Hill3, Robert A S Ariëns4.   

Abstract

Paroxysmal nocturnal hemoglobinuria is a rare acquired hematologic disorder, the most serious complication of which is thrombosis. The increased incidence of thrombosis in paroxysmal nocturnal hemoglobinuria is still poorly understood, but unlike many other thrombotic disorders, predominantly involves complement-mediated mechanisms. This review article discusses the different factors that contribute to the increased risk of thrombosis in paroxysmal nocturnal hemoglobinuria. Paroxysmal nocturnal hemoglobinuria leads to a complex and multifaceted prothrombotic state due to the pathological effects of platelet activation, intravascular hemolysis and neutrophil/monocyte activation. Platelet and endothelial microparticles as well as oxidative stress may play a role. Impaired fibrinolysis has also been observed and may be caused by several mechanisms involving interactions between complement activation, coagulation and fibrinolysis. While many factors may affect thrombosis in paroxysmal nocturnal hemoglobinuria, the relative contribution of each mechanism that has been implicated is difficult to quantify. Further studies, including novel in vivo and in vitro thrombosis models, are required in order to define the role of the individual mechanisms contributing to thrombosis, impaired fibrinolysis and clarify other complement-driven prothrombotic mechanisms in paroxysmal nocturnal hemoglobinuria. Copyright
© 2018 Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29246924     DOI: 10.3324/haematol.2017.177618

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

Review 1.  Anticoagulating patients with high-risk acquired thrombophilias.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Authors:  Morag Griffin; Peter Hillmen; Talha Munir; Stephen Richards; Louise Arnold; Kathryn Riley; Anita Hill
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

Review 3.  Red blood cells: the forgotten player in hemostasis and thrombosis.

Authors:  J W Weisel; R I Litvinov
Journal:  J Thromb Haemost       Date:  2019-01-07       Impact factor: 5.824

4.  Venous thromboembolic events during warm autoimmune hemolytic anemia.

Authors:  Sylvain Audia; Benoit Bach; Maxime Samson; Daniela Lakomy; Jean-Baptiste Bour; Bénédicte Burlet; Julien Guy; Laurence Duvillard; Marine Branger; Vanessa Leguy-Seguin; Sabine Berthier; Marc Michel; Bernard Bonnotte
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

Review 5.  Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy.

Authors:  Kiruphagaran Thangaraju; Sabari Nath Neerukonda; Upendra Katneni; Paul W Buehler
Journal:  Int J Mol Sci       Date:  2020-12-25       Impact factor: 5.923

Review 6.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

7.  Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.

Authors:  Austin G Kulasekararaj; Morag Griffin; Saskia Langemeijer; Kensuke Usuki; Alexander Kulagin; Masayo Ogawa; Ji Yu; Arshad Mujeebuddin; Jun-Ichi Nishimura; Jong Wook Lee; Régis Peffault de Latour
Journal:  Eur J Haematol       Date:  2022-06-16       Impact factor: 3.674

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.